Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: Direct evidence from sympathetic neural recording

References

• Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, . Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompen-sated heart failure national registry (ADHERE). Am Heart J. 2005;149:209–16.
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, . Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The task force on acute heart failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416.
   PubMed Web of Science ®Google Scholar
• Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous ino-tropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002; 4:515–29.
   PubMed Web of Science ®Google Scholar
• Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, . Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. Am Heart J. 2002; 144:1102–8.
   PubMed Web of Science ®Google Scholar
• Pathak A, Velez-Roa S, Xhaet O, Najem B, van de Borne P. Dose-dependent effect of dobutamine on chemoreflex activity in healthy volunteers. Br J Clin Pharmacol. 2006; 62:272–9.
   Google Scholar
• Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol.1995;25:794–801.
   PubMed Web of Science ®Google Scholar
• Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibencla-mide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997; 333:249–59.
   PubMed Web of Science ®Google Scholar
• Kaheinen P, Pollesello P, Hertelendi Z, Borbely A, Szilagyi S, Nissinen E, . Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition. Basic Clin Pharmacol Toxicol. 2006; 98:74–8.
   Google Scholar
• Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, . Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36:1903–12.
   PubMed Web of Science ®Google Scholar
• Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol. 2006; 98:1641–5.
   Google Scholar
• Grassi G, Bolla G, Quarti-Trevano F, Arenare F, Brambilla G, Mancia G. Sympathetic activation in congestive heart failure: Reproducibility of neuroadrenergic markers. Eur J Heart Fail. 2008; 10:1186–91.
   PubMed Web of Science ®Google Scholar
• Despas F, Detis N, Dumonteil N, Labrunee M, Bellon B, Franchitto N, . Excessive sympathetic activation in heart failure with chronic renal failure: Role of chemoreflex activation. J Hypertens. 2009; 27:1849–54.
   Google Scholar
• Vallbo AB, Hagbarth KE, Wallin BG. Mcroneurography: how the technique developed and its role in the investigation of the sympathetic nervous system. J Appl Physiol. 2004; 96:1262–9.
   PubMed Web of Science ®Google Scholar
• Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, . Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol. 1994; 46:191–6.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006; 8:105–10.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, . Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. JAMA 2007;297:1883–91.
   PubMed Web of Science ®Google Scholar
• Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Lev-osimendan, a new positive inotropic drug, decreases myocar-dial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5–11.
   PubMed Web of Science ®Google Scholar
• LaRovere MT, Pinna GD, Maestri R, Robbi E, Caporotondi A, Guazzotti G, . Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J Am Coll Cardiol. 2009;53:193–9.
   Google Scholar
• Hainsworth R. Reflexes from the heart. Physiol Rev. 1991;71:617–58.
   PubMed Web of Science ®Google Scholar
• al-Timman JK, Hainsworth R. Reflex vascular responses to changes in left ventricular pressures, heart rate and inotropic state in dogs. Exp Physiol. 1992;77:455–69.
   Google Scholar
• Fitzpatrick AP, Banner N, Cheng A, Yacoub M, Sutton R. Vasovagal reactions may occur after orthotopic heart transplantation. J Am Coll Cardiol. 1993;21:1132–7.
   PubMedGoogle Scholar
• Parissis JT, Karavidas A, Bistola V, Arapi S, Paraskevaidis IA, Farmakis D, . Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 2008;197:278–82.
   PubMed Web of Science ®Google Scholar
• Miura T, Kawamura S, Tatsuno H, Ikeda Y, Mikami S, Iwamoto H, . Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia. Circulation 2001;104:1053–8.
   Google Scholar
• Abramson BL, Ando S, Notarius CF, Rongen GA, Floras JS. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure. Circulation 1999;99:1810–5.
   PubMed Web of Science ®Google Scholar
• Floras JS. Inhibitory effect of atrial natriuretic factor on sympathetic ganglionic neurotransmission in humans. Am J Physiol. 1995;269:R406–12.
   Google Scholar
• Parissis JT, Andreadou I, Markantonis SL, Bistola V, Louka A, Pyriochou A, . Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007;195:e210–5.
   PubMed Web of Science ®Google Scholar
• Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, . Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apopto-sis mediators in patients with decompensated advanced heart failure. Am J Cardiol. 2004;93:1309–12.
   PubMed Web of Science ®Google Scholar